Christophe Weber - Takeda Pharmaceutical CEO

TAK Stock  USD 14.19  0.20  1.39%   

CEO

Mr. Christophe Weber was serving as President, Chief Executive Officer and Representative Director in Takeda Pharmaceutical Company Limited since April 1, 2015. He used to work for GlaxoSmithKline K.K. since 2015.
Age 58
Tenure 9 years
Address 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668
Phone81 3 3278 2111
Webhttps://www.takeda.com

Takeda Pharmaceutical Management Efficiency

The company has Return on Asset of 0.0261 % which means that on every $100 spent on assets, it made $0.0261 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0276 %, implying that it generated $0.0276 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.1 this year, although the value of Return On Capital Employed will most likely fall to 0.05. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 16.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 383.9 B.
The company has 4.38 T in debt with debt to equity (D/E) ratio of 0.81, which is OK given its current industry classification. Takeda Pharmaceutical has a current ratio of 1.16, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Takeda Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Takeda Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Takeda Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Takeda to invest in growth at high rates of return. When we think about Takeda Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

William SiboldMadrigal Pharmaceuticals
58
Chen SchorMadrigal Pharmaceuticals
41
Geoffrey RotsteinEquillium
N/A
Michael McMullenAgilent Technologies
63
Shawn IadonatoKineta Inc
54
Manuel MDMustang Bio
70
Frans Blom23Andme Holding Co
40
Eric MBASeres Therapeutics
48
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 47347 people. Takeda Pharmaceutical Co (TAK) is traded on New York Stock Exchange in USA. It is located in 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 and employs 49,095 people. Takeda Pharmaceutical is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Takeda Pharmaceutical Leadership Team

Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ian Clark, Independent Director
Gregory Hayes, Interim CFO, Corporate Secretary
Constantine Saroukos, CFO Director
Salvatore MD, Member Policy
Neil Swift, interim President and CEO
C Wasser, Director
Lori Walton, Director
Masami Iijima, Independent Director
Christophe Weber, President, Chief Executive Officer, Representative Director
Masahiro Sakane, Independent Chairman of the Executive Board
Seigo Izumo, Chair Board
Olivier Bohuon, Independent Director
Gabriele Ricci, Chief Officer
JeanLuc Butel, Independent Director
Salvatore Alesci, Member Policy
Iwaaki Taniguchi, Senior Department
Michel Orsinger, Independent Director
Dennis Fentie, Director
Peter Bures, Director
Shiro Kuniya, Independent Director
Emiko Azuma, Independent Director
Christopher OReilly, Global Finance
Toshiyuki Shiga, Independent Director
Dave Glover, IR Contact Officer
Steven Gillis, Independent Director
Haruhiko Hirate, Member Board
Norimasa Takeda, Chief Controller
Masato Iwasaki, President of Japan Pharma Business Unit, Director
Yasuhiko Yamanaka, Director
Emiko Higashi, Independent Director
Janet LeeSheriff, Director
Patricia Wilson, Independent Director
Andrew Plump, President of Research & Development, Vice President of Subsidiary, Director
Costa Saroukos, Chief Financial Officer, Director
Tokumasa Takeda, IR Contact Officer
Yoshiaki Fujimori, Independent Director
Koji Hatsukawa, Independent Director

Takeda Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Takeda Stock analysis

When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.12)
Dividend Share
184
Earnings Share
0.37
Revenue Per Share
1.3 K
Quarterly Revenue Growth
0.013
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.